4-[(S)-2-Azetidin-1-yl-1-(4-fluorophenyl)-ethylamino]-quinazoline-8-carboxamide

ID: ALA4876446

Chembl Id: CHEMBL4876446

PubChem CID: 67608743

Max Phase: Preclinical

Molecular Formula: C21H20F3N5O

Molecular Weight: 415.42

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  NC(=O)c1cccc2c(N[C@H](CN3CCC3)c3cccc(C(F)(F)F)c3)ncnc12

Standard InChI:  InChI=1S/C21H20F3N5O/c22-21(23,24)14-5-1-4-13(10-14)17(11-29-8-3-9-29)28-20-16-7-2-6-15(19(25)30)18(16)26-12-27-20/h1-2,4-7,10,12,17H,3,8-9,11H2,(H2,25,30)(H,26,27,28)/t17-/m1/s1

Standard InChI Key:  YFBSBJBNKSZCLY-QGZVFWFLSA-N

Associated Targets(Human)

AKT1 Tchem Serine/threonine-protein kinase AKT (9192 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AURKB Tchem Aurora kinase B/Inner centromere protein (233 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 415.42Molecular Weight (Monoisotopic): 415.1620AlogP: 3.61#Rotatable Bonds: 6
Polar Surface Area: 84.14Molecular Species: NEUTRALHBA: 5HBD: 2
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 7.99CX LogP: 2.91CX LogD: 2.22
Aromatic Rings: 3Heavy Atoms: 30QED Weighted: 0.64Np Likeness Score: -1.37

References

1. DeSelm L, Huck B, Lan R, Neagu C, Potnick J, Xiao Y, Chen X, Jones R, Richardson TE, Heasley BH, Haxell T, Moore J, Tian H, Georgi K, Rohdich F, Sutton A, Johnson T, Mochalkin I, Jackson J, Lin J, Crowley L, Machl A, Clark A, Wilker E, Sherer B, Goutopoulos A..  (2021)  Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers.,  64  (19.0): [PMID:34596404] [10.1021/acs.jmedchem.1c01087]

Source